Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.

@article{Kuritzky2014SafetyAE,
  title={Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.},
  author={Louis Kuritzky and Guillermo E Umpierrez and Jean Marie Eko{\'e} and Leonardo Guadalupe Mancillas-Adame and Laura Fern{\'a}ndez Land{\'o}},
  journal={Postgraduate medicine},
  year={2014},
  volume={126 6},
  pages={60-72}
}
BACKGROUND Type 2 diabetes (T2D) is an increasingly common endocrine disorder that is characterized by chronic hyperglycemia and tissue compartment abnormalities, including macrovascular and microvascular complications. More than 90% of patients with T2D will be diagnosed and treated in the primary care setting. One of the relatively recent additions to the increasing array of approved antidiabetic medications is the glucagon-like peptide-1 receptor agonist class. Mechanisms of action for… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Controlled release of biologics for the treatment of type 2 diabetes.

Journal of controlled release : official journal of the Controlled Release Society • 2016
View 8 Excerpts
Highly Influenced

Dulaglutide for the treatment of type 2 diabetes.

Expert opinion on biological therapy • 2017

Similar Papers

Loading similar papers…